This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDNegative Net Change AVDLPositive Net Change SKYEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFENegative Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKPositive Net Change MRKNegative Net Change GILDPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYNegative Net Change JAZZNegative Net Change ETNBNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSNegative Net Change KNSAPositive Net Change GMABPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
by Ahan Chakraborty
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
BMYPositive Net Change NVONegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
by Sundeep Ganoria
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
by Kanishka Das
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
SNYPositive Net Change TEVAPositive Net Change FOLDNegative Net Change
biotechs
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
ALNYPositive Net Change NVSPositive Net Change PFENegative Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is IPF the Next Big Market Opportunity for United Therapeutics?
by Sundeep Ganoria
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
UTHRNegative Net Change INSMNegative Net Change LQDANegative Net Change
biotechs medical
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
by Zacks Equity Research
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
by Ahan Chakraborty
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
by Zacks Equity Research
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
BMYPositive Net Change MRKNegative Net Change ABEONegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
by Kanishka Das
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
JAZZNegative Net Change ACADPositive Net Change AXSMPositive Net Change
biotechs
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
by Sundeep Ganoria
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
RDYNegative Net Change TEVAPositive Net Change ALVOPositive Net Change
biotechs medical
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
by Zacks Equity Research
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
HALOPositive Net Change ABBVNegative Net Change ANIPPositive Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change RARENegative Net Change
biotechnology biotechs medical pharmaceuticals
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
by Sundeep Ganoria
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
CRMDNegative Net Change CDTXNegative Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
AZNPositive Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
by Kanishka Das
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
SNYPositive Net Change RIGLPositive Net Change FOLDNegative Net Change
biotechs medical